Inhibitory Effects of Euscaphic Acid in the Atopic Dermatitis Model by Reducing Skin Inflammation and Intense Pruritus

Atopic dermatitis (AD) is a complex and multifactorial skin disease characterized by skin inflammation and intense pruritus. There are many commercially available treatments such as topical corticosteroids and immunosuppressants to treat of AD, but their effectiveness is limited, and frequent use of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Inflammation 2022-08, Vol.45 (4), p.1680-1691
Hauptverfasser: Jeong, Na-Hee, Lee, Soyoung, Choi, Young-Ae, Song, Kyung-Sik, Kim, Sang-Hyun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1691
container_issue 4
container_start_page 1680
container_title Inflammation
container_volume 45
creator Jeong, Na-Hee
Lee, Soyoung
Choi, Young-Ae
Song, Kyung-Sik
Kim, Sang-Hyun
description Atopic dermatitis (AD) is a complex and multifactorial skin disease characterized by skin inflammation and intense pruritus. There are many commercially available treatments such as topical corticosteroids and immunosuppressants to treat of AD, but their effectiveness is limited, and frequent use of these treatments can cause serious side effects. Therefore, the development of new therapeutic agents is necessary for the treatment of AD. Hence, an alternative agent that was derived from natural products that are effective and safe for AD treatment was investigated using experimental models. The biological activity of euscaphic acid has anti-inflammatory, anticoagulant, and antioxidant effects. Despite the various biomedical properties of euscaphic acid, its therapeutic effects on AD have not been well studied. In this study, we investigated the effects of euscaphic acid on skin inflammation and pruritus in AD mouse model. The effects of euscaphic acid were investigated in activated human epidermal keratinocytes and leukemia T lymphoblast cell lines, and Dermatophagoides farina extract and 2,4-dinitrochlorobenzene-induced AD mouse model. Euscaphic acid ameliorated AD properties, such as the expression of inflammatory cytokines and activation of transcription factors. In addition, euscaphic acid reduced critical factors for pruritus such as immunoglobulin E hyperproduction, mast cell invasion, and interleukin-33 expression. Taken together, euscaphic acid could be a potent therapeutic agent for the treatment of AD.
doi_str_mv 10.1007/s10753-022-01652-x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2637315223</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2676401694</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-3b00ffb28f03e7403fae56eef8bfd38d3b1f6b4ff219b6d8e518e7c52acbef8f3</originalsourceid><addsrcrecordid>eNp90U2PFCEQBmBiNO64-gc8GBIvXlqBGpru42QddZI1Gj_OpKGLHdZuGIE2O_9e1lk18eCJpHiqqPAS8pSzl5wx9SpzpiQ0TIiG8VaK5uYeWXGpoBFStffJikHLGuh7dUYe5XzNGOv6Dh6SM5BVCAUr8mMX9t74EtORbp1DWzKNjm6XbIfD3lu6sX6kPtCyR7op8VBLrzHNQ_HFZ_o-jjhRc6SfcFysD1f087eKd8FNw3yLYqBDGGuhYMhIP6Yl-bLkx-SBG6aMT-7Oc_L1zfbLxbvm8sPb3cXmsrGgZGnAMOacEZ1jgGrNwA0oW0TXGTdCN4LhrjVr5wTvTTt2KHmHykoxWFORg3Py4jT3kOL3BXPRs88Wp2kIGJesRQsKuBQCKn3-D72OSwp1u6pUu65f3K-rEidlU8w5odOH5OchHTVn-jYVfUpF11T0r1T0TW16djd6MTOOf1p-x1ABnECuV-EK09-3_zP2J3pcmdk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2676401694</pqid></control><display><type>article</type><title>Inhibitory Effects of Euscaphic Acid in the Atopic Dermatitis Model by Reducing Skin Inflammation and Intense Pruritus</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Jeong, Na-Hee ; Lee, Soyoung ; Choi, Young-Ae ; Song, Kyung-Sik ; Kim, Sang-Hyun</creator><creatorcontrib>Jeong, Na-Hee ; Lee, Soyoung ; Choi, Young-Ae ; Song, Kyung-Sik ; Kim, Sang-Hyun</creatorcontrib><description>Atopic dermatitis (AD) is a complex and multifactorial skin disease characterized by skin inflammation and intense pruritus. There are many commercially available treatments such as topical corticosteroids and immunosuppressants to treat of AD, but their effectiveness is limited, and frequent use of these treatments can cause serious side effects. Therefore, the development of new therapeutic agents is necessary for the treatment of AD. Hence, an alternative agent that was derived from natural products that are effective and safe for AD treatment was investigated using experimental models. The biological activity of euscaphic acid has anti-inflammatory, anticoagulant, and antioxidant effects. Despite the various biomedical properties of euscaphic acid, its therapeutic effects on AD have not been well studied. In this study, we investigated the effects of euscaphic acid on skin inflammation and pruritus in AD mouse model. The effects of euscaphic acid were investigated in activated human epidermal keratinocytes and leukemia T lymphoblast cell lines, and Dermatophagoides farina extract and 2,4-dinitrochlorobenzene-induced AD mouse model. Euscaphic acid ameliorated AD properties, such as the expression of inflammatory cytokines and activation of transcription factors. In addition, euscaphic acid reduced critical factors for pruritus such as immunoglobulin E hyperproduction, mast cell invasion, and interleukin-33 expression. Taken together, euscaphic acid could be a potent therapeutic agent for the treatment of AD.</description><identifier>ISSN: 0360-3997</identifier><identifier>EISSN: 1573-2576</identifier><identifier>DOI: 10.1007/s10753-022-01652-x</identifier><identifier>PMID: 35257273</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Acids ; Animal models ; Animals ; Antioxidants ; Atopic dermatitis ; Biological activity ; Biomedical and Life Sciences ; Biomedicine ; Corticosteroids ; Cytokines - metabolism ; Dermatitis ; Dermatitis, Atopic - chemically induced ; Dinitrochlorobenzene - pharmacology ; Disease Models, Animal ; Eczema ; Immunoglobulin E ; Immunology ; Immunosuppressive agents ; Inflammation ; Inflammation - drug therapy ; Inflammation - metabolism ; Internal Medicine ; Keratinocytes ; Mice ; Mice, Inbred BALB C ; Natural products ; Original Article ; Pathology ; Pharmacology/Toxicology ; Pruritus ; Pruritus - drug therapy ; Pruritus - metabolism ; Rheumatology ; Skin ; Skin diseases ; Transcription activation ; Transcription factors ; Triterpenes ; Tumor cell lines</subject><ispartof>Inflammation, 2022-08, Vol.45 (4), p.1680-1691</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-3b00ffb28f03e7403fae56eef8bfd38d3b1f6b4ff219b6d8e518e7c52acbef8f3</citedby><cites>FETCH-LOGICAL-c375t-3b00ffb28f03e7403fae56eef8bfd38d3b1f6b4ff219b6d8e518e7c52acbef8f3</cites><orcidid>0000-0002-6160-7354</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10753-022-01652-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10753-022-01652-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35257273$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jeong, Na-Hee</creatorcontrib><creatorcontrib>Lee, Soyoung</creatorcontrib><creatorcontrib>Choi, Young-Ae</creatorcontrib><creatorcontrib>Song, Kyung-Sik</creatorcontrib><creatorcontrib>Kim, Sang-Hyun</creatorcontrib><title>Inhibitory Effects of Euscaphic Acid in the Atopic Dermatitis Model by Reducing Skin Inflammation and Intense Pruritus</title><title>Inflammation</title><addtitle>Inflammation</addtitle><addtitle>Inflammation</addtitle><description>Atopic dermatitis (AD) is a complex and multifactorial skin disease characterized by skin inflammation and intense pruritus. There are many commercially available treatments such as topical corticosteroids and immunosuppressants to treat of AD, but their effectiveness is limited, and frequent use of these treatments can cause serious side effects. Therefore, the development of new therapeutic agents is necessary for the treatment of AD. Hence, an alternative agent that was derived from natural products that are effective and safe for AD treatment was investigated using experimental models. The biological activity of euscaphic acid has anti-inflammatory, anticoagulant, and antioxidant effects. Despite the various biomedical properties of euscaphic acid, its therapeutic effects on AD have not been well studied. In this study, we investigated the effects of euscaphic acid on skin inflammation and pruritus in AD mouse model. The effects of euscaphic acid were investigated in activated human epidermal keratinocytes and leukemia T lymphoblast cell lines, and Dermatophagoides farina extract and 2,4-dinitrochlorobenzene-induced AD mouse model. Euscaphic acid ameliorated AD properties, such as the expression of inflammatory cytokines and activation of transcription factors. In addition, euscaphic acid reduced critical factors for pruritus such as immunoglobulin E hyperproduction, mast cell invasion, and interleukin-33 expression. Taken together, euscaphic acid could be a potent therapeutic agent for the treatment of AD.</description><subject>Acids</subject><subject>Animal models</subject><subject>Animals</subject><subject>Antioxidants</subject><subject>Atopic dermatitis</subject><subject>Biological activity</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Corticosteroids</subject><subject>Cytokines - metabolism</subject><subject>Dermatitis</subject><subject>Dermatitis, Atopic - chemically induced</subject><subject>Dinitrochlorobenzene - pharmacology</subject><subject>Disease Models, Animal</subject><subject>Eczema</subject><subject>Immunoglobulin E</subject><subject>Immunology</subject><subject>Immunosuppressive agents</subject><subject>Inflammation</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - metabolism</subject><subject>Internal Medicine</subject><subject>Keratinocytes</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Natural products</subject><subject>Original Article</subject><subject>Pathology</subject><subject>Pharmacology/Toxicology</subject><subject>Pruritus</subject><subject>Pruritus - drug therapy</subject><subject>Pruritus - metabolism</subject><subject>Rheumatology</subject><subject>Skin</subject><subject>Skin diseases</subject><subject>Transcription activation</subject><subject>Transcription factors</subject><subject>Triterpenes</subject><subject>Tumor cell lines</subject><issn>0360-3997</issn><issn>1573-2576</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp90U2PFCEQBmBiNO64-gc8GBIvXlqBGpru42QddZI1Gj_OpKGLHdZuGIE2O_9e1lk18eCJpHiqqPAS8pSzl5wx9SpzpiQ0TIiG8VaK5uYeWXGpoBFStffJikHLGuh7dUYe5XzNGOv6Dh6SM5BVCAUr8mMX9t74EtORbp1DWzKNjm6XbIfD3lu6sX6kPtCyR7op8VBLrzHNQ_HFZ_o-jjhRc6SfcFysD1f087eKd8FNw3yLYqBDGGuhYMhIP6Yl-bLkx-SBG6aMT-7Oc_L1zfbLxbvm8sPb3cXmsrGgZGnAMOacEZ1jgGrNwA0oW0TXGTdCN4LhrjVr5wTvTTt2KHmHykoxWFORg3Py4jT3kOL3BXPRs88Wp2kIGJesRQsKuBQCKn3-D72OSwp1u6pUu65f3K-rEidlU8w5odOH5OchHTVn-jYVfUpF11T0r1T0TW16djd6MTOOf1p-x1ABnECuV-EK09-3_zP2J3pcmdk</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Jeong, Na-Hee</creator><creator>Lee, Soyoung</creator><creator>Choi, Young-Ae</creator><creator>Song, Kyung-Sik</creator><creator>Kim, Sang-Hyun</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6160-7354</orcidid></search><sort><creationdate>20220801</creationdate><title>Inhibitory Effects of Euscaphic Acid in the Atopic Dermatitis Model by Reducing Skin Inflammation and Intense Pruritus</title><author>Jeong, Na-Hee ; Lee, Soyoung ; Choi, Young-Ae ; Song, Kyung-Sik ; Kim, Sang-Hyun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-3b00ffb28f03e7403fae56eef8bfd38d3b1f6b4ff219b6d8e518e7c52acbef8f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acids</topic><topic>Animal models</topic><topic>Animals</topic><topic>Antioxidants</topic><topic>Atopic dermatitis</topic><topic>Biological activity</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Corticosteroids</topic><topic>Cytokines - metabolism</topic><topic>Dermatitis</topic><topic>Dermatitis, Atopic - chemically induced</topic><topic>Dinitrochlorobenzene - pharmacology</topic><topic>Disease Models, Animal</topic><topic>Eczema</topic><topic>Immunoglobulin E</topic><topic>Immunology</topic><topic>Immunosuppressive agents</topic><topic>Inflammation</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - metabolism</topic><topic>Internal Medicine</topic><topic>Keratinocytes</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Natural products</topic><topic>Original Article</topic><topic>Pathology</topic><topic>Pharmacology/Toxicology</topic><topic>Pruritus</topic><topic>Pruritus - drug therapy</topic><topic>Pruritus - metabolism</topic><topic>Rheumatology</topic><topic>Skin</topic><topic>Skin diseases</topic><topic>Transcription activation</topic><topic>Transcription factors</topic><topic>Triterpenes</topic><topic>Tumor cell lines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jeong, Na-Hee</creatorcontrib><creatorcontrib>Lee, Soyoung</creatorcontrib><creatorcontrib>Choi, Young-Ae</creatorcontrib><creatorcontrib>Song, Kyung-Sik</creatorcontrib><creatorcontrib>Kim, Sang-Hyun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Inflammation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jeong, Na-Hee</au><au>Lee, Soyoung</au><au>Choi, Young-Ae</au><au>Song, Kyung-Sik</au><au>Kim, Sang-Hyun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibitory Effects of Euscaphic Acid in the Atopic Dermatitis Model by Reducing Skin Inflammation and Intense Pruritus</atitle><jtitle>Inflammation</jtitle><stitle>Inflammation</stitle><addtitle>Inflammation</addtitle><date>2022-08-01</date><risdate>2022</risdate><volume>45</volume><issue>4</issue><spage>1680</spage><epage>1691</epage><pages>1680-1691</pages><issn>0360-3997</issn><eissn>1573-2576</eissn><abstract>Atopic dermatitis (AD) is a complex and multifactorial skin disease characterized by skin inflammation and intense pruritus. There are many commercially available treatments such as topical corticosteroids and immunosuppressants to treat of AD, but their effectiveness is limited, and frequent use of these treatments can cause serious side effects. Therefore, the development of new therapeutic agents is necessary for the treatment of AD. Hence, an alternative agent that was derived from natural products that are effective and safe for AD treatment was investigated using experimental models. The biological activity of euscaphic acid has anti-inflammatory, anticoagulant, and antioxidant effects. Despite the various biomedical properties of euscaphic acid, its therapeutic effects on AD have not been well studied. In this study, we investigated the effects of euscaphic acid on skin inflammation and pruritus in AD mouse model. The effects of euscaphic acid were investigated in activated human epidermal keratinocytes and leukemia T lymphoblast cell lines, and Dermatophagoides farina extract and 2,4-dinitrochlorobenzene-induced AD mouse model. Euscaphic acid ameliorated AD properties, such as the expression of inflammatory cytokines and activation of transcription factors. In addition, euscaphic acid reduced critical factors for pruritus such as immunoglobulin E hyperproduction, mast cell invasion, and interleukin-33 expression. Taken together, euscaphic acid could be a potent therapeutic agent for the treatment of AD.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>35257273</pmid><doi>10.1007/s10753-022-01652-x</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-6160-7354</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0360-3997
ispartof Inflammation, 2022-08, Vol.45 (4), p.1680-1691
issn 0360-3997
1573-2576
language eng
recordid cdi_proquest_miscellaneous_2637315223
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Acids
Animal models
Animals
Antioxidants
Atopic dermatitis
Biological activity
Biomedical and Life Sciences
Biomedicine
Corticosteroids
Cytokines - metabolism
Dermatitis
Dermatitis, Atopic - chemically induced
Dinitrochlorobenzene - pharmacology
Disease Models, Animal
Eczema
Immunoglobulin E
Immunology
Immunosuppressive agents
Inflammation
Inflammation - drug therapy
Inflammation - metabolism
Internal Medicine
Keratinocytes
Mice
Mice, Inbred BALB C
Natural products
Original Article
Pathology
Pharmacology/Toxicology
Pruritus
Pruritus - drug therapy
Pruritus - metabolism
Rheumatology
Skin
Skin diseases
Transcription activation
Transcription factors
Triterpenes
Tumor cell lines
title Inhibitory Effects of Euscaphic Acid in the Atopic Dermatitis Model by Reducing Skin Inflammation and Intense Pruritus
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T16%3A11%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibitory%20Effects%20of%20Euscaphic%20Acid%20in%20the%20Atopic%20Dermatitis%20Model%20by%20Reducing%20Skin%20Inflammation%20and%20Intense%20Pruritus&rft.jtitle=Inflammation&rft.au=Jeong,%20Na-Hee&rft.date=2022-08-01&rft.volume=45&rft.issue=4&rft.spage=1680&rft.epage=1691&rft.pages=1680-1691&rft.issn=0360-3997&rft.eissn=1573-2576&rft_id=info:doi/10.1007/s10753-022-01652-x&rft_dat=%3Cproquest_cross%3E2676401694%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2676401694&rft_id=info:pmid/35257273&rfr_iscdi=true